Brain Advance Access originally published online on February 2, 2005
Brain 2005 128(3):678-687; doi:10.1093/brain/awh399
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas
1 Clinic for Nuclear Medicine (KME), 2 Institute of Nuclear Chemistry (INC), 3 Institute of Medicine (IME) and 4 Brain Imaging Center West, Research Center Jülich, Jülich, 5 Department of Nuclear Medicine, 6 Department of Neurosurgery and 7 Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany
Correspondence to: Dirk Pauleit, Clinic for Nuclear Medicine (KME), Research Center Jülich, Leo-Brandt-Strasse; 52425 Jülich, Germany E-mail: pauleit{at}web.de
MRI is commonly used to determine the location and extent of cerebral gliomas. We investigated whether the diagnostic accuracy of MRI could be improved by the additional use of PET with the amino acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET). In a prospective study, PET with FET and MRI was performed in 31 patients with suspected cerebral gliomas. PET and MRIs were co-registered and 52 neuronavigated tissue biopsies were taken from lesions with both abnormal MRI signal and increased FET uptake (match), as well as from areas with abnormal MR signal but normal FET uptake or vice versa (mismatch). Biopsy sites were labelled by intracerebral titanium pellets. The diagnostic performance for the identification of cellular tumour tissue was analysed for either MRI alone or MRI combined with FET PET using alternative free response receiver operating characteristic curves (ROCs). Histologically, 26 biopsy samples corresponded to cellular glioma tissue and 26 to peritumoral brain tissue. The diagnostic performance, as determined by the area under the ROC curve (Az), was Az = 0.80 for MRI alone and Az = 0.98 for the combined MRI and FET PET approach (P < 0.001). MRI yielded a sensitivity of 96% for the detection of tumour tissue but a specificity of only 53%, and combined use of MRI and FET PET yielded a sensitivity of 93% and a specificity of 94%. Combined use of MRI and FET PET in patients with cerebral gliomas significantly improves the identification of cellular glioma tissue and allows definite histological tumour diagnosis. Thus, our findings may have considerable impact on target selection for diagnostic biopsies as well as therapy planning.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Samnick, B. F. Romeike, T. Lehmann, I. Israel, C. Rube, A. Mautes, C. Reiners, and C.-M. Kirsch Efficacy of Systemic Radionuclide Therapy with p-131I-Iodo-L-Phenylalanine Combined with External Beam Photon Irradiation in Treating Malignant Gliomas J. Nucl. Med., December 1, 2009; 50(12): 2025 - 2032. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Stadlbauer, O. Prante, C. Nimsky, E. Salomonowitz, M. Buchfelder, T. Kuwert, R. Linke, and O. Ganslandt Metabolic Imaging of Cerebral Gliomas: Spatial Correlation of Changes in O-(2-18F-Fluoroethyl)-L-Tyrosine PET and Proton Magnetic Resonance Spectroscopic Imaging J. Nucl. Med., May 1, 2008; 49(5): 721 - 729. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W. Floeth, M. Sabel, G. Stoffels, D. Pauleit, K. Hamacher, H.-J. Steiger, and K.-J. Langen Prognostic Value of 18F-Fluoroethyl-L-Tyrosine PET and MRI in Small Nonspecific Incidental Brain Lesions J. Nucl. Med., May 1, 2008; 49(5): 730 - 737. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Salber, G. Stoffels, D. Pauleit, A.-M. Oros-Peusquens, N. J. Shah, P. Klauth, K. Hamacher, H. H. Coenen, and K.-J. Langen Differential Uptake of O-(2-18F-Fluoroethyl)-L-Tyrosine, L-3H-Methionine, and 3H-Deoxyglucose in Brain Abscesses J. Nucl. Med., December 1, 2007; 48(12): 2056 - 2062. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schiepers, W. Chen, T. Cloughesy, M. Dahlbom, and S.-C. Huang 18F-FDOPA Kinetics in Brain Tumors J. Nucl. Med., October 1, 2007; 48(10): 1651 - 1661. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Chen Clinical Applications of PET in Brain Tumors J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W. Floeth, D. Pauleit, M. Sabel, G. Stoffels, G. Reifenberger, M. J. Riemenschneider, P. Jansen, H. H. Coenen, H.-J. Steiger, and K.-J. Langen Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma J. Nucl. Med., April 1, 2007; 48(4): 519 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Wyss, N. Spaeth, G. Biollaz, J. Pahnke, P. Alessi, E. Trachsel, V. Treyer, B. Weber, D. Neri, and A. Buck Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 Gliomas and Correlation with 131I-SIP(L19), a Marker of Angiogenesis J. Nucl. Med., April 1, 2007; 48(4): 608 - 614. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Chen, D. H.S. Silverman, S. Delaloye, J. Czernin, N. Kamdar, W. Pope, N. Satyamurthy, C. Schiepers, and T. Cloughesy 18F-FDOPA PET Imaging of Brain Tumors: Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy J. Nucl. Med., June 1, 2006; 47(6): 904 - 911. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W. Floeth, D. Pauleit, M. Sabel, G. Reifenberger, G. Stoffels, W. Stummer, F. Rommel, K. Hamacher, and K.-J. Langen 18F-FET PET Differentiation of Ring-Enhancing Brain Lesions J. Nucl. Med., May 1, 2006; 47(5): 776 - 782. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Popperl, F. W. Kreth, J. Herms, W. Koch, J. H. Mehrkens, F. J. Gildehaus, H. A. Kretzschmar, J. C. Tonn, and K. Tatsch Analysis of 18F-FET PET for Grading of Recurrent Gliomas: Is Evaluation of Uptake Kinetics Superior to Standard Methods? J. Nucl. Med., March 1, 2006; 47(3): 393 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Pauleit, A. Zimmermann, G. Stoffels, D. Bauer, J. Risse, M. O. Fluss, K. Hamacher, H. H. Coenen, and K.-J. Langen 18F-FET PET Compared with 18F-FDG PET and CT in Patients with Head and Neck Cancer J. Nucl. Med., February 1, 2006; 47(2): 256 - 261. [Abstract] [Full Text] [PDF] |
||||
